Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 8.3% – Should You Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares fell 8.3% during trading on Tuesday. The stock traded as low as $11.08 and last traded at $11.11. Approximately 1,127,780 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 5,103,586 shares. The stock had previously closed at $12.11.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on NTLA shares. Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price on the stock in a research report on Friday, August 7th. Citizens Jmp restated a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a research note on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Finally, Wall Street Zen cut shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $21.44.

Read Our Latest Analysis on Intellia Therapeutics

Intellia Therapeutics Price Performance

The company’s 50-day simple moving average is $12.02 and its 200 day simple moving average is $13.00.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Intellia Therapeutics had a negative net margin of 805.75% and a negative return on equity of 64.74%. The business had revenue of $7.16 million for the quarter, compared to the consensus estimate of $9.74 million. During the same quarter in the prior year, the business posted ($0.92) EPS. The firm’s revenue for the quarter was down 47.8% compared to the same quarter last year. On average, sell-side analysts predict that Intellia Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the transaction, the chief executive officer directly owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is owned by insiders.

Institutional Trading of Intellia Therapeutics

Several large investors have recently made changes to their positions in NTLA. BlackRock Inc. bought a new position in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $260,721,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Intellia Therapeutics by 24.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company’s stock worth $43,484,000 after purchasing an additional 708,094 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Intellia Therapeutics by 20.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock worth $29,709,000 after purchasing an additional 386,261 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Intellia Therapeutics during the first quarter worth approximately $17,913,000. Finally, Bank of America Corp DE boosted its position in Intellia Therapeutics by 11.2% during the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares during the period. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

Recommended Stories

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.